Embolx

Sunnyvale, United States Founded: 2013 • Age: 13 yrs
Catheter-based system for localized cancer therapy is being developed.

About Embolx

Embolx is a company based in Sunnyvale (United States) founded in 2013. It operates as a Direct-to-Consumer (D2C), and HealthTech. Embolx has raised $500 thousand across 3 funding rounds from investors including HHS. Embolx offers products and services including Sniper Balloon Occlusion Microcatheter, Soldier High Flow Microcatheter, and Sniper G3 Balloon Occlusion Microcatheter. Embolx operates in a competitive market with competitors including Augmedics, TriSalus Life Sciences, Proprio, ClearPoint Neuro and IMRIS Deerfield Imaging, among others.

  • Headquarter Sunnyvale, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Embolx, Inc.
Operational Areas
Healthcare → Medical Devices & Diagnostics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $500 K (USD)

    in 3 rounds

  • Latest Funding Round
    $1.86 M (USD), Grant

    Sep 25, 2015

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Embolx

Embolx offers a comprehensive portfolio of products and services, including Sniper Balloon Occlusion Microcatheter, Soldier High Flow Microcatheter, and Sniper G3 Balloon Occlusion Microcatheter. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Used for targeted arterial embolization in medical procedures.

Designed for high-flow delivery in embolization treatments.

Enhanced microcatheter for efficient and targeted embolization.

People of Embolx
Headcount 1-10
Employee Profiles 4
Board Members and Advisors 4
Employee Profiles
People
Tom Breton
Manager of Research & Development
People
Michael Allen
President & CEO
People
Haley McGregor
Marketing Manager
People
Chris Goodrow
Southwest Territory Sales Manager

Unlock access to complete

Board Members and Advisors
people
Norman Gitis
Chairman

Unlock access to complete

Funding Insights of Embolx

Embolx has successfully raised a total of $500K across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.86 million completed in September 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Grant — $1.9M
  • First Round

    (04 Feb 2014)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2015 Amount Grant - Embolx Valuation

investors

HHS
May, 2014 Amount Seed - Embolx Valuation

investors

Feb, 2014 Amount Seed - Embolx Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Embolx

Embolx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Embolx

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Embolx

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Embolx Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Embolx

Embolx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Augmedics, TriSalus Life Sciences, Proprio, ClearPoint Neuro and IMRIS Deerfield Imaging, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Augmented reality systems for guiding surgical procedures are developed.
domain founded_year HQ Location
Developer of drug delivery devices to treat cancers
domain founded_year HQ Location
Visualization systems for surgical procedures are developed using machine learning.
domain founded_year HQ Location
Software and hardware solutions for MRI-guided surgical planning are provided.
domain founded_year HQ Location
Surgical theatres with ceiling mounted mobile imaging devices to enhance intraoperative workflow
domain founded_year HQ Location
Robotic surgery platform for bone procedures is developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Embolx

When was Embolx founded?

Embolx was founded in 2013 and raised its 1st funding round 1 year after it was founded.

Where is Embolx located?

Embolx is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.

Is Embolx a funded company?

Embolx is a funded company, having raised a total of $500K across 3 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Feb 04, 2014.

What does Embolx do?

Embolx is engaged in the development and innovation of microcatheters for arterial embolization procedures. Solutions are provided for targeted medical interventions using high-pressure and low-pressure techniques. The healthcare sector, specifically interventional radiology, is served through products like the Sniper Balloon Occlusion Microcatheter and Soldier High Flow Microcatheter. Advancements are continuously made, as seen with the release of the Sniper G3, enhancing efficiency and usability in medical treatments.

Who are the top competitors of Embolx?

Embolx's top competitors include Augmedics, Proprio and TriSalus Life Sciences.

What products or services does Embolx offer?

Embolx offers Sniper Balloon Occlusion Microcatheter, Soldier High Flow Microcatheter, and Sniper G3 Balloon Occlusion Microcatheter.

Who are Embolx's investors?

Embolx has 1 investor. Key investors include HHS.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available